With this in mind perhaps, Dexcom has launched its Stelo device ... for its products having mass-market appeal, in order to keep the share price buoyant. I have fallen into this trap myself ...

So I told him the Abbott Lingo and Dexcom Stelo were both good options for people who are not ... Neither company was set up for a bulk purchase, so each person had to buy their own. The price points ...

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.

DexCom, Inc. DXCM is scheduled to release fourth-quarter 2024 results on Feb. 13, after the closing bell. In the last ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Barclays analyst Matt Miksic lowered the firm’s price target on DexCom (DXCM) to $92 from $113 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical technology outlook ...

Q4 2024 Management View Kevin Sayer, CEO, highlighted that Q4 2024 organic revenue growth was 8%, contributing to a full-year organic growth of 12%, aligned with guidance. The company ended 2024 with ...